<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Methyltestosterone: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Methyltestosterone: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Methyltestosterone: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11986" href="/d/html/11986.html" rel="external">see "Methyltestosterone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F195469"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Methitest</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F195485"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Androgen</li></ul></div>
<div class="block doa drugH1Div" id="F195472"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b8423721-7a23-4fed-bf36-91a0c75f98e6">Breast cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic (females):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for the secondary treatment of advancing inoperable metastatic (skeletal) mammary cancer in patients who are 1 to 5 years postmenopausal, use has been replaced by other agents. Current guidelines for the management of metastatic breast cancer do not include recommendations for the use of methyltestosterone in the treatment of this condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27217461','lexi-content-ref-34678411']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27217461','lexi-content-ref-34678411'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 50 to 200 mg daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a304d815-b9b0-4ebf-801d-acfbba32b737">Delayed puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delayed puberty (males):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for the treatment of delayed puberty in males, use has been replaced by other agents. Current guidelines for the management of pubertal induction and transition to adult sex hormone replacement do not include recommendations for the use of methyltestosterone in the treatment of this condition (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35353710']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35353710'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 10 to 50 mg daily; limit treatment duration to 4 to 6 months; use lower range of dosing and individualize dose based on response and tolerability.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990598"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, patients with kidney disease may be at an increased risk of fluid retention.</p></div>
<div class="block doha drugH1Div" id="F50987981"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment prior to therapy: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). However, patients with hepatic disease may be at an increased risk of fluid retention.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment during therapy: Discontinue use if abnormal LFTs or cholestatic hepatitis with jaundice occur.</p></div>
<div class="block doe drugH1Div" id="F195473"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. Although Beers Criteria recommends to avoid use unless indicated for hypogonadism, increased risk of liver toxicity has made methyltestosterone obsolete for this indication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824','lexi-content-ref-29562364']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824','lexi-content-ref-29562364'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F25479280"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a304d815-b9b0-4ebf-801d-acfbba32b737">Delayed puberty</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Delayed puberty:</b> Adolescent males: Oral: Refer to adult dosing.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3f989c1-c657-45bc-868f-5fe34b05cfb5">Hypogonadotropic hypogonadism and primary hypogonadism</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypogonadotropic hypogonadism (congenital or acquired) and primary hypogonadism (congenital or acquired):</b> Adolescent males: Oral: Refer to adult dosing.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51129970"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, patients with renal disease may be at an increased risk of fluid retention.</p></div>
<div class="block dohp drugH1Div" id="F51129971"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). However, patients with hepatic disease may be at an increased risk of fluid retention.</p></div>
<div class="block adr drugH1Div" id="F195449"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Anxiety, depression, headache, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, androgenetic alopecia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Change in libido, gynecomastia (males), hirsutism (females), hypercalcemia, hypercholesterolemia, menstrual disease (includes amenorrhea)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Benign prostatic hypertrophy (males), impotence (males), mastalgia (females), oligospermia (males; at high doses), priapism (males), testicular atrophy (males), virilization (males and females)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Clotting factors suppression, polycythemia, prostate carcinoma (males)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal liver function tests, cholestatic hepatitis, hepatic insufficiency, hepatic necrosis, jaundice, peliosis hepatitis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, hepatocellular neoplasm, hepatotoxicity (idiosyncratic; Chalasani 2014)</p></div>
<div class="block coi drugH1Div" id="F195462"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;">Men with breast cancer or with known or suspected prostate cancer; women who are or may become pregnant.</p></div>
<div class="block war drugH1Div" id="F195446"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular events: Available studies are inconclusive regarding the risk of developing major adverse cardiovascular events such as nonfatal myocardial infarction, stroke, or cardiovascular death following testosterone use; most data are specific to males who were prescribed testosterone therapy (Basaria 2010; Corona 2014; Finkle 2014; Morgentaler 2015; Vigen 2013). Evaluate patients for cardiovascular risk factors prior to initiating therapy and monitor closely during therapy for cardiovascular events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Prolonged use and/or high doses may cause peliosis hepatis, hepatic neoplasms including hepatocellular carcinoma, cholestatic hepatitis, and jaundice. Discontinue if cholestatic hepatitis with jaundice or abnormal liver function tests occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oligospermia: May cause oligospermia and reduced ejaculatory volume after prolonged administration or excessive dosage.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polycythemia: May increase hematocrit requiring dose adjustment or discontinuation. Withhold initial treatment in patients with hematocrit &gt;48% or &gt;50% if living at higher altitudes. Discontinue therapy if hematocrit exceeds 54% (ES [Bhasin 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Priapism: Priapism or excessive sexual stimulation may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Venous thromboembolism: Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have been reported with testosterone products. Evaluate patients with symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those with acute shortness of breath for PE. Discontinue therapy if a venous thromboembolism is suspected. Use in patients with thrombophilia is not recommended (ES [Bhasin 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benign prostatic hyperplasia: Androgens may worsen benign prostatic hyperplasia (BPH); do not use in patients with severe lower urinary tract symptoms (American Urological Association/International Prostate Symptom Score &gt;19) (ES [Bhasin 2018]). Discontinue therapy if urethral obstruction develops in patients with BPH (use lower dose if restarted).</p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: May cause hypercalcemia (by stimulating osteolysis) in patients with breast cancer; discontinue if hypercalcemia occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Use with caution in patients with diseases that may be exacerbated by fluid retention, including cardiac impairment; may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate cancer: May increase the risk of prostate cancer. Withhold therapy pending urological evaluation in patients with palpable prostate nodule or induration, PSA &gt;4 ng/mL, or PSA &gt;3 ng/mL in patients at high risk of prostate cancer (ES [Bhasin 2018]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep apnea: May potentiate sleep apnea in some male patients, especially those with risk factors (eg, obesity, chronic lung disease). Withhold initial treatment in patients with untreated obstructive sleep apnea (ES [Bhasin 2018]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Females: During treatment for metastatic breast cancer, females should be monitored for signs of virilization (eg, deepening of voice, hirsutism, acne, clitoromegaly, menstrual irregularities); discontinue if mild virilization is present to prevent irreversible symptoms.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May accelerate bone maturation (without producing compensatory gain in linear growth) and premature closure of the epiphyses in children; in prepubertal children, perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers. Use with caution in males with delayed puberty.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse/misuse/diversion: Anabolic steroids may be abused, typically at doses higher than recommended and in combination with other anabolic androgenic steroids; abuse may be associated with serious cardiovascular and psychiatric adverse reactions. Inform patients of the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids; if abuse is suspected, check serum testosterone levels (testosterone levels may be in the normal or subnormal range in males abusing synthetic testosterone derivatives). Consider the possibility of abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dependence: Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented; however, dependence may occur when used outside of approved dosage/indications.</p></div>
<div class="block foc drugH1Div" id="F195457"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Methitest: 10 mg [scored]</p></div>
<div class="block geq drugH1Div" id="F195442"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F195463"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (methylTESTOSTERone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $83.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F195487"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-III</p></div>
<div class="block adm drugH1Div" id="F28107296"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer orally. </p></div>
<div class="block admp drugH1Div" id="F52613312"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer orally.</p></div>
<div class="block hazard drugH1Div" id="F49104554"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 3]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block use drugH1Div" id="F195459"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer, metastatic (females):</b> Secondarily in females with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal; has also been used in premenopausal females with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for the secondary treatment of advancing inoperable metastatic (skeletal) mammary cancer in patients who are 1 to 5 years postmenopausal, use has been replaced by other agents. Current guidelines for the management of metastatic breast cancer do not include recommendations for the use of methyltestosterone in the treatment of this condition (ASCO [Rugo 2016]; ESMO [Gennari 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Delayed puberty (males):</b> To stimulate puberty in carefully selected males with clearly delayed puberty.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for the treatment of delayed puberty in males, use has been replaced by other agents. Current guidelines for the management of pubertal induction and transition to adult sex hormone replacement do not include recommendations for the use of methyltestosterone in the treatment of this condition (Endo-ERN [Nordenström 2022]).</p></div>
<div class="block mst drugH1Div" id="F195493"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">MethylTESTOSTERone may be confused with medroxyPROGESTERone, methylPREDNISolone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Methyltestosterone is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years of age and older due to its potential for cardiac problems and potential risks in men with prostate cancer (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299703"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F195451"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Androgens may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).  Management: Consider avoiding concomitant use of androgens and cyclosporine. If concomitant use is unavoidable, monitor serum cyclosporine concentrations and for signs and symptoms of hepatotoxicity. Cyclosporine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypertension-Associated Agents: May enhance the hypertensive effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308221"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in females who may become pregnant. Use of methyltestosterone may impair fertility; oligospermia may occur in males and amenorrhea may occur in females.</p></div>
<div class="block pri drugH1Div" id="F13388443"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in females who are pregnant. Exposure during pregnancy may cause virilization of the external genitalis of the female fetus, including clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. The degree of masculinization is dose related and most likely to occur when androgens are administered in the first trimester. If a patient becomes pregnant while taking androgens, counsel on the potential hazard to the fetus.</p></div>
<div class="block brc drugH1Div" id="F20616287"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if methyltestosterone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F195454"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">LFTs, lipid panel, hemoglobin and hematocrit (at 3 to 6 months then annually). Monitor urine and serum calcium and signs of virilization in females treated for breast cancer. Serum glucose (may be decreased by testosterone, monitor patients with diabetes). Monitor for cardiovascular events closely during therapy. Monitor PSA if clinically indicated. In prepubertal patients, perform radiologic examination of wrist and hand every 6 months.</p></div>
<div class="block pha drugH1Div" id="F195445"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Endogenous androgen stimulates receptors in organs and tissues to promote growth and development of male sex organs and maintains secondary sex characteristics in androgen-deficient males</p></div>
<div class="block phk drugH1Div" id="F195461"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 98% bound to sex hormone-binding globulin</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Variable: 10 to 100 minutes</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~90%); feces (~6%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F195464"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Testosteron Streuli</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Methyltestost | Virormone</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Teston</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Methyl Testosteron</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Methyl Testosteron</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Testovis</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Enarmon | Enerfa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Testo</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Methyltestoste</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Methyltestosteron</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Android-10 | Methitest | Testred | Virilon</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Methyltestosteron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cox-m | Methyl Testosteron | Testohof forte</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Afro</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fu li hormone | Metesmin | Methyl Testosteron | Methyltesterone | Rex | Sinnow | Teriman | Tespo</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Methyltestosteron</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Oreton</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Methyl Testosteron</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Android (methyltestosterone) capsules [prescribing information]. Bridgewater, NJ: Valeant; September 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20592293">
<a name="20592293"></a>Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. <i>N Engl J Med</i>. 2010;363(2):109-122. doi:10.1056/NEJMoa1000485<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/20592293/pubmed" id="20592293" target="_blank">20592293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562364">
<a name="29562364"></a>Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/29562364/pubmed" id="29562364" target="_blank">29562364</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25139126">
<a name="25139126"></a>Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. <i>Expert Opin Drug Saf</i>. 2014;13(10):1327-1351. doi:10.1517/14740338.2014.950653<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/25139126/pubmed" id="25139126" target="_blank">25139126</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Endocrine Society news release. Endocrine Society calls for large-scale studies to evaluate testosterone therapy risks. https://www.endocrine.org/news-room/press-release-archives/2014/endocrine-society-calls-for-large-scale-studies-to-evaluate-testosterone-therapy-risks. Updated February 7, 2014. Accessed April 30, 2015.</div>
</li>
<li>
<div class="reference">
                  FDA Drug Safety Communications. FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Food and Drug Administration website. <a href="http://www.fda.gov/downloads/Drugs/DrugSafety/UCM436270.pdf" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM436270.pdf</a>. Published March 3, 2015. Accessed January 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24489673">
<a name="24489673"></a>Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. <i>PLoS One</i>. 2014;9(1):e85805. doi:10.1371/journal.pone.0085805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/24489673/pubmed" id="24489673" target="_blank">24489673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27736313">
<a name="27736313"></a>Fleseriu M, Hashim IA, Karavitaki N, et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(11):3888-3921. doi:10.1210/jc.2016-2118<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/27736313/pubmed" id="27736313" target="_blank">27736313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34678411">
<a name="34678411"></a>Gennari A, André F, Barrios CH, et al; ESMO Guidelines Committee. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. <i>Ann Oncol</i>. 2021;32(12):1475-1495. doi:10.1016/j.annonc.2021.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/34678411/pubmed" id="34678411" target="_blank">34678411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26355962">
<a name="26355962"></a>Goodman N, Guay A, Dandona P, Dhindsa S, Faiman C, Cunningham GR; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology (ACE) position statement on the association of testosterone and cardiovascular risk. <i>Endocr Pract</i>. 2015;21(9):1066-1073. doi:10.4158/EP14434.PS<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/26355962/pubmed" id="26355962" target="_blank">26355962</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Methitest (methyltestosterone) [prescribing information]. Bridgewater, NJ: Amneal Pharmaceuticals LLC; October 2018.</div>
</li>
<li>
<div class="reference">
                  Methyltestosterone capsules [prescribing information]. East Windsor, NJ: Novitium Pharma LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25636998">
<a name="25636998"></a>Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. <i>Mayo Clin Proc</i>. 2015;90(2):224-251. doi:10.1016/j.mayocp.2014.10.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/25636998/pubmed" id="25636998" target="_blank">25636998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25617174">
<a name="25617174"></a>Nieschlag E. Current topics in testosterone replacement of hypogonadal men. <i>Best Pract Res Clin Endocrinol Metab</i>. 2015;29(1):77-90. doi:10.1016/j.beem.2014.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/25617174/pubmed" id="25617174" target="_blank">25617174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35353710">
<a name="35353710"></a>Nordenström A, Ahmed SF, van den Akker E, et al. Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline. <i>Eur J Endocrinol</i>. 2022;186(6):G9-G49. doi:10.1530/EJE-22-0073<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/35353710/pubmed" id="35353710" target="_blank">35353710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27217461">
<a name="27217461"></a>Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. <i>J Clin Oncol</i>. 2016;34(25):3069-3103. doi:10.1200/JCO.2016.67.1487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/27217461/pubmed" id="27217461" target="_blank">27217461</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24193080">
<a name="24193080"></a>Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. <i>JAMA</i>. 2013;310(17):1829-1836. doi:10.1001/jama.2013.280386<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/24193080/pubmed" id="24193080" target="_blank">24193080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21047236">
<a name="21047236"></a>Weikert C, Pischon T, Weikert S. Adverse events associated with testosterone administration. <i>N Engl J Med</i>. 2010;363(19):1865; author reply 1866-1867. doi:10.1056/NEJMc1009326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/methyltestosterone-drug-information/abstract-text/21047236/pubmed" id="21047236" target="_blank">21047236</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9640 Version 192.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
